Chlorthalidone for High Blood Pressure in Older Adults

Phase < 1

Waitlist Available

Led By TAKURO WASHIO, Ph.D.

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 2 weeks post intervention

Summary

This trial aims to study the effects of drug treatment for high blood pressure on brain health in older adults. The researchers will recruit participants with high blood pressure and give them either the drug treatment or a placebo

Who is the study for?

This trial is for older adults with high blood pressure who have not yet started treatment. Participants should be generally healthy, without conditions that could interfere with the study or pose additional risks.

What is being tested?

The study tests if chlorthalidone (a drug for high blood pressure) affects brain blood flow and cognitive function compared to a placebo over two weeks. Researchers will monitor changes in participants' brain health and nervous system regulation.

What are the potential side effects?

Potential side effects of chlorthalidone may include dizziness, dehydration, electrolyte imbalance, and possible impact on kidney function. Placebo has no active ingredients but can cause perceived side effects due to the 'placebo effect.'

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 2 weeks post intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 2 weeks post intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 2 weeks post intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Cerebral blood flow from baseline at 2 weeks post intervention

Change in Muscle sympathetic nerve activity (MSNA) from baseline at 2 weeks post intervention

Change in cognitive performance from baseline at 2 weeks post intervention via NIH Toolbox Cognitive Battery

+1 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Antihypertensive drug treatment ArmActive Control1 Intervention

Participants will take a fixed dose of chlorthalidone (a diuretic, 25 mg orally once daily) for two week, with study visits for laboratory assessment at before and after intervention.

Group II: Placebo treatment ArmPlacebo Group1 Intervention

Participants will receive placebo treatment for two weeks, with study visits for laboratory assessment at before and after intervention.

Do I qualify?Apply below to find out